Table 2. List of selected... | American Society of Hematology

Table 2.

List of selected anticoagulation trials in COVID-19

Patient population	Trial name and trial identifier	Intervention	Comparison	Outcome	Status
Hospitalized (non-ICU)	ACTION Trial³¹	Therapeutic rivaroxaban or LMWH	Usual care thromboprophylaxis	Mortality, length of stay, and oxygen use	Published
	ATTACC³⁰ NCT04372589	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	ACTIV-4a³⁰ NCT04505774	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	REMAP-CAP³⁰ NCT02735707	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
Hospitalized (ICU)	ATTACC²⁹ NCT04372589	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	ACTIV-4a²⁹ NCT04505774	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	REMAP-CAP²⁹ NCT02735707	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	INSPIRATION³² NCT04486508	Intermediate-dose heparin or LMWH	Prophylactic-dose heparin or LMWH	Composite of VTE, arterial thrombosis, or ECMO	Published
Post discharge	ACTIV-4 Convalescent NCT04650087	Prophylactic-dose apixaban	Placebo	Composite outcome of symptomatic DVT, PE, other VTE, ischemic stroke, acute MI, other ATE, and all-cause mortality	Recruiting
Outpatient	ACTIV-4c NCT04498273	Prophylactic-dose apixaban, therapeutic- dose apixaban, ASA	Placebo	Composite of symptomatic DVT or PE, ATE, MI, ischemic stroke, hospitalization for cardiovascular/pulmonary events, and all-cause mortality	Recruiting
Outpatient	PREVENT-HD NCT04508023	Prophylactic-dose rivaroxaban	Placebo	Composite of symptomatic VTE, MI, ischemic stroke, systemic embolism, acute limb ischemia, all-cause hospitalization, and all-cause mortality	Recruiting

Patient population	Trial name and trial identifier	Intervention	Comparison	Outcome	Status
Hospitalized (non-ICU)	ACTION Trial³¹	Therapeutic rivaroxaban or LMWH	Usual care thromboprophylaxis	Mortality, length of stay, and oxygen use	Published
	ATTACC³⁰ NCT04372589	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	ACTIV-4a³⁰ NCT04505774	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	REMAP-CAP³⁰ NCT02735707	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
Hospitalized (ICU)	ATTACC²⁹ NCT04372589	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	ACTIV-4a²⁹ NCT04505774	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	REMAP-CAP²⁹ NCT02735707	Therapeutic heparin or LMWH	Usual care thromboprophylaxis	Hospital discharge without need for organ support	Preprint
	INSPIRATION³² NCT04486508	Intermediate-dose heparin or LMWH	Prophylactic-dose heparin or LMWH	Composite of VTE, arterial thrombosis, or ECMO	Published
Post discharge	ACTIV-4 Convalescent NCT04650087	Prophylactic-dose apixaban	Placebo	Composite outcome of symptomatic DVT, PE, other VTE, ischemic stroke, acute MI, other ATE, and all-cause mortality	Recruiting
Outpatient	ACTIV-4c NCT04498273	Prophylactic-dose apixaban, therapeutic- dose apixaban, ASA	Placebo	Composite of symptomatic DVT or PE, ATE, MI, ischemic stroke, hospitalization for cardiovascular/pulmonary events, and all-cause mortality	Recruiting
Outpatient	PREVENT-HD NCT04508023	Prophylactic-dose rivaroxaban	Placebo	Composite of symptomatic VTE, MI, ischemic stroke, systemic embolism, acute limb ischemia, all-cause hospitalization, and all-cause mortality	Recruiting

ASA, aspirin; ECMO, extracorporeal membrane oxygenation; MI, myocardial infarction.